Automation, Monitoring, and Standardization of Cell Product Manufacturing

Frontiers in Bioengineering and Biotechnology

卷:8

Meletios-Nikolaos Doulgkeroglou¹  Bastian Niessing¹  Dimitrios I. Zeugolis³  Vincent Ronfard⁴  Yves Bayon⁵  Robert H. Schmitt⁶  Jackie Damen⁶  Stephen J. Szilvassy⁸  Alessia Di Nubila⁹  Lynn Csontos¹⁰  Wing Chang¹⁰  Patrick Kugelmeier¹¹  Sharon Louis¹¹  Niels König¹² 

[1] Developmental Engineering Laboratory, National University of Ireland Galway, Galway, Ireland;

[2] 0HairClone, Manchester, United Kingdom;

[3] 1Medtronic – Sofradim Production, Trévoux, France;

[4] College System of Pharmacy, University of North Texas Health Science Center, Fort Worth, TX, United States;

[5] Cutiss AG, Zurich, Switzerland;

[6] Fraunhofer Institute for Production Technology, Aachen, Germany;

[7] Kugelmeiers Ltd., Zollikerberg, Switzerland;

[8] Production Engineering Cluster, RWTH Aachen University, Aachen, Germany;

[9] Regenerative, Modular &

[10] STEMCELL Technologies Inc., Vancouver, BC, Canada;

[11] STEMCELL Technologies Ltd., Cambridge, United Kingdom;

[12] Science Foundation Ireland, Centre for Research in Medical Devices, National University of Ireland Galway, Galway, Ireland;

关键词: cell therapy;    scalability;    manufacturing;    monitoring;    spheroid culture;    biorectors;   

DOI  :  10.3389/fbioe.2020.00811

来源: DOAJ

【 摘 要 】

Although regenerative medicine products are at the forefront of scientific research, technological innovation, and clinical translation, their reproducibility and large-scale production are compromised by automation, monitoring, and standardization issues. To overcome these limitations, new technologies at software (e.g., algorithms and artificial intelligence models, combined with imaging software and machine learning techniques) and hardware (e.g., automated liquid handling, automated cell expansion bioreactor systems, automated colony-forming unit counting and characterization units, and scalable cell culture plates) level are under intense investigation. Automation, monitoring and standardization should be considered at the early stages of the developmental cycle of cell products to deliver more robust and effective therapies and treatment plans to the bedside, reducing healthcare expenditure and improving services and patient care.

【 授权许可】

Unknown